FTC report exposes big pharma middlemen inflating drug prices by up to 7,736%
Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) marked up specialty generic drug prices by up to 7,736 percent between 2017 and 2022.
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
Health care in the US is notoriously complicated and opaque, with a veritable alphabet soup of companies and government agencies that influence how much Americans pay for drugs. Now President ...
The U.S. district judge in Cleveland, Ohio handling a galaxy of claims stemming from the prescription opioid epidemic on ...
Tucked into the bipartisan budget deal that President-elect Donald Trump’s allies torpedoed earlier this month was a rare and significant attempt to reform the mechanics of America’s drug ...
"I don't know who these middlemen are, but they are rich," he said. "We're going to knock out the middleman. We're going to get drug costs down at levels that nobody has ever seen before," Trump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback